Frazier Life Sciences Management L.P. Has $120.43 Million Stock Holdings in Krystal Biotech, Inc. $KRYS

Frazier Life Sciences Management L.P. reduced its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS) by 29.1% in the 4th quarter, Holdings Channel reports. The fund owned 488,460 shares of the company’s stock after selling 200,000 shares during the quarter. Krystal Biotech accounts for 3.2% of Frazier Life Sciences Management L.P.’s portfolio, making the stock its 9th biggest position. Frazier Life Sciences Management L.P.’s holdings in Krystal Biotech were worth $120,425,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of KRYS. Soleus Capital Management L.P. increased its holdings in shares of Krystal Biotech by 108.9% in the second quarter. Soleus Capital Management L.P. now owns 922,958 shares of the company’s stock worth $126,870,000 after acquiring an additional 481,200 shares in the last quarter. Norges Bank bought a new stake in shares of Krystal Biotech in the fourth quarter worth about $70,159,000. William Blair Investment Management LLC increased its holdings in shares of Krystal Biotech by 152.1% in the fourth quarter. William Blair Investment Management LLC now owns 376,340 shares of the company’s stock worth $92,783,000 after acquiring an additional 227,038 shares in the last quarter. UBS Group AG increased its holdings in shares of Krystal Biotech by 970.8% in the fourth quarter. UBS Group AG now owns 159,595 shares of the company’s stock worth $39,347,000 after acquiring an additional 177,922 shares in the last quarter. Finally, Millennium Management LLC increased its holdings in shares of Krystal Biotech by 1,083.8% in the third quarter. Millennium Management LLC now owns 148,713 shares of the company’s stock worth $26,252,000 after acquiring an additional 136,151 shares in the last quarter. 86.29% of the stock is currently owned by institutional investors.

Insider Activity at Krystal Biotech

In related news, EVP John Charles Thomas sold 642 shares of the stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $302.03, for a total transaction of $193,903.26. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $308.11, for a total value of $7,702,750.00. Following the transaction, the insider directly owned 1,378,155 shares of the company’s stock, valued at $424,623,337.05. This trade represents a 1.78% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 13.10% of the company’s stock.

Krystal Biotech Stock Performance

NASDAQ:KRYS opened at $317.97 on Friday. The company has a market cap of $9.37 billion, a PE ratio of 42.51 and a beta of 0.53. Krystal Biotech, Inc. has a 52-week low of $127.99 and a 52-week high of $331.49. The stock has a 50-day simple moving average of $288.44 and a 200 day simple moving average of $267.89.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings results on Monday, May 4th. The company reported $1.83 EPS for the quarter, beating the consensus estimate of $1.45 by $0.38. Krystal Biotech had a return on equity of 19.25% and a net margin of 53.92%.The firm had revenue of $116.36 million during the quarter, compared to analysts’ expectations of $112.11 million. On average, research analysts predict that Krystal Biotech, Inc. will post 7.83 earnings per share for the current fiscal year.

Analyst Ratings Changes

KRYS has been the subject of a number of research reports. Guggenheim increased their price objective on Krystal Biotech from $224.00 to $284.00 and gave the stock a “buy” rating in a report on Wednesday, February 25th. HC Wainwright reiterated a “buy” rating and set a $310.00 price objective on shares of Krystal Biotech in a report on Monday, June 1st. Wolfe Research initiated coverage on Krystal Biotech in a report on Friday, March 27th. They set a “peer perform” rating for the company. Evercore reiterated an “outperform” rating and set a $300.00 price objective on shares of Krystal Biotech in a report on Tuesday, May 5th. Finally, Wall Street Zen upgraded Krystal Biotech from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. Ten analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $324.11.

Krystal Biotech Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.